Tachyon Ventures provides early-stage smart capital to entrepreneurs in the fields of medicine, biotech, and bioengineering. They have a network of scientists at leading research institutions.

Tachyon Ventures

Tachyon Ventures | 190 followers on LinkedIn. Early-stage life sciences VC | Tachyon Ventures invests in early-stage life sciences ventures at the forefront of medicine, biotech and bioengineering. We seek scientific teams pursuing ambitious goals and building platforms backed by industry-leading research and IP in the fields of immunotherapy, gene therapy / genetic engineering, organ engineering, and stem cell / regenerative medicine. We provide funding at pre-seed, seed and series A stage for teams with encouraging early test results, and a clear path-to-market.

Managing Partner The Agency RE

Josep Turro Bassols

Innovation | Design | Biotech VC | Quantum Computing

Cristina Escoda

Tachyon Ventures is thrilled to continue to support Axonis Therapeutics in their newly announced $115 million Series A financing to develop novel neuro-medicines targeting KC22. We invested alongside lead investors Cormorant Asset Management, LP and venBio , and MRL Ventures Fund LLC , Perceptive Advisors , Solasta Ventures and Lumira Ventures . Congratulations to Joanna Stanicka , Axonis' CEO, and the rest of the team! https://lnkd.in/dpn_E9Ns

Fun fact: Tachyon Partner Cristina Escoda previously co-founded ORCA Computing, now NVIDIA's quantum partner. If you're near Barcelona, join Cristina at the Barcelona Deep Tech Summit and learn from her diverse experiences – from building organizations in deep tech to working in finance at HSBC and D.E. Shaw & Co in NYC.

Did you know? Trauma-induced bleeding is the leading cause of death in Americans aged between one and 46 years old. When we get injured, our bodies engage in a series of complex processes to naturally stop bleeding, called hemostasis. Platelets play an essential role in hemostasis, and the transfusion of platelets is part of the standard procedure for patients who are rapidly losing large volumes of blood. However, hospitals encounter several challenges in maintaining platelets for emergency patient use: dependency on donors, blood-type matching, storage under specific conditions, and a short shelf-life. That's where Haima Therapeutics ' technology, Synthoplate, comes in. Synthoplate is a platelet-inspired synthetic cell therapy that mimics the mechanisms that platelets use to control bleeding. Importantly, Synthoplate overcomes many of the challenges around availability, matching, storage and portability that donor platelets have. It's the kind of technology that can have a dramatic impact on preventable causes of death like uncontrolled bleeding, for patients of all ages – and a stellar addition to Tachyon's portfolio. https://lnkd.in/eEJt-hrd

We're always excited when we meet teams that introduce us to new scientific mechanisms. Thanks to Andrew Rudd and his team, we got to delve into palmitoylation as a method of deactivating harmful proteins, and are now investors in their company Palm Therapeutics . Learn more about palmitoylation's role in various forms of cancer and neurodegenerative diseases on our blog. https://lnkd.in/eAktVXe6

🚨🧠 New Neuroscience News: 06/09 A quiet week for neuroscience but still some important developments: EnClear Therapies have gained additional funding from new partners Brain Tumor Investment Fund , a subsidiary of National Brain Tumor Society and Sontag Innovation Fund Fund along with continued support from existing investors such as Amgen Ventures, Founders Fund , Thiel Bio Fund, Tachyon Ventures and Bioverge Funds LLC ECHO I . This financing means EnClear will expedite the development of their groundbreaking technology within Neuro-Oncology, they will also be able to bolster pre-clinical programs aimed at transforming the treatment landscape of CNS diseases AcuraStem announced $4M in grant funding from the California Institute for Regenerative Medicine (CIRM) . The funding will be used to advance the development of their UNC13A program by utilising their tech platform iNeuroRx® with the target of combating neurodegenerative diseases but specifically ALS & FDT Adaptin Bio, Inc. have gained FDA clearance off the back of their IND application for APTN-101. APTN-101 is a program which targets glioblastoma (GBM), the most common and aggressive primary brain tumour. The clearance allows Adaptin to initiate a first-in-human Phase I clinical trial NRG Therapeutics have been awarded a non-dilutive grant from TARGET ALS FOUNDATION, INC in collaboration with Biospective Inc. NRG will use the funding to support their discovery programme for a treatment for ALS/MND Neuronetics, Inc. have highlighted their progress of their NeuroStar towards the goal of saving thousands of lives through their Advanced Therapy for depression. Currently the platform has potentially saved 1,771 lives having treated 88,533 lives patients with the aim of saving 3,325 lives #neuroscience #sjneuro

Grant Smillie

Discover groundbreaking research published in Nature Medicine revealing that mutations in a small non-coding gene called RNU4-2 causes a neurodevelopmental disorder that affects tens of thousands of people worldwide. The discovery is significant, as it represents one of the most common single-gene genetic causes of such disorders, ranking second only to Rett syndrome. Notably, these mutations are typically spontaneous and not inherited, providing important insights into the nature of the condition. This pivotal study was led by our very own Tachyon Ventures partner, Dr. Ernest Turro, who is also an associate professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. 🔬 Read more about these exciting findings on NBC News: https://lnkd.in/gyfvYSwk

TACH

VC:TACHYON

Tachyon Ventures